Neonatal lupus erythrematosus: Difference between revisions

Jump to navigation Jump to search
Line 9: Line 9:


==Historical Perspective==
==Historical Perspective==
The first case reported by Aylward in 1928, who described two siblings with Complete heart block born to a mother who had Sjogren’s syndrome. But the first report linking autoimmune disease in mother with cutaneous lupus was McCuistion and Schoch in 1954.  In 1957 Hogg noted the possible relation between autoimmune disease of the mother and congenital heart block in her child.  Finally in 1980 Weston reported the association of neonatal lupus (NLE) with maternal anti-Ro auto- antibodies.


==Classification==
==Classification==

Revision as of 18:00, 23 August 2013


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords:; NL, neonatal lupus

Overview

Historical Perspective

Classification

Pathophysiology

Neonatal lupus (NL) is presumed to result from transplacental passage of maternal anti-SSA/Ro and/or anti-SSB/La antibodies. The precise mechanism of injury to specific tissues, such as the skin and heart, is not known. In addition to the traditional Ro antigen of 60kD, another antigen of 52kD has been identified. Whether this second antigen is really “Ro” remains controversial since the Ro52 does not contain an RNA binding domain. Antibodies with a specificity for the 52 kD component of the SSA/Ro protein (Ro52) are more frequently found and are present at higher concentrations in the serum of children with congenital heart block (CHB) and their mothers.[1][2][3]

Genetics

Associated Conditions

Gross Pathology

Microscopic Pathology

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical / poisoning No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal / Ortho No underlying causes
Neurologic No underlying causes
Nutritional / Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Opthalmologic No underlying causes
Overdose / Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal / Electrolyte No underlying causes
Rheum / Immune / Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Dental No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

  • A...
  • Z...

Make sure that each diagnosis is linked to a page.

Differentiating type page name here from other Diseases

Epidemiology and Demographics

Age

Gender

Race

Developed Countries

Developing Countries

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History

A directed history should be obtained to ascertain

Symptoms

"Type symptom here" is pathognomonic of the "type disease name here".

"Type non specific symptoms" may be present.

Past Medical History

Family History

Social History

Occupational

Alcohol

The frequency and amount of alcohol consumption should be characterized.

Drug Use

Smoking

Allergies

Physical Examination

Appearance of the Patient

Vital Signs

Skin

Head

Eyes

Ear

Nose

Mouth

Throat

Heart

Lungs

Abdomen

Extremities

Neurologic

Genitals

Other

Laboratory Findings

Electrolyte and Biomarker Studies

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Pharmacotherapy

Acute Pharmacotherapies

Chronic Pharmacotherapies

Surgery and Device Based Therapy

Indications for Surgery

Pre-Operative Assessment

Post-Operative Management

Transplantation

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

References

  1. Buyon JP, Winchester RJ, Slade SG, Arnett F, Copel J, Friedman D; et al. (1993). "Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies". Arthritis Rheum. 36 (9): 1263–73. PMID 8216420.
  2. Silverman ED, Buyon J, Laxer RM, Hamilton R, Bini P, Chu JL; et al. (1995). "Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus". Clin Exp Immunol. 100 (3): 499–505. PMC 1534456. PMID 7774062.
  3. Salomonsson S, Dörner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M (2002). "A serologic marker for fetal risk of congenital heart block". Arthritis Rheum. 46 (5): 1233–41. doi:10.1002/art.10232. PMID 12115229.


Template:WikiDoc Sources